Faes Farma : Q1 earnings in line, FY 2023 guidance reiterated
>Sales momentum remains slow while margins post some improvement - Total Q1 2023 revenues reached € 118m (+3% y-o-y vs +2% in Q422 and -6% in Q322). By division, sales of traditional products in Spain posted some sequential improvement yet remained in the red (-4% y-o-y vs -7% in Q4 2022 and -9% in Q3 2022), reflecting stagnant sales of Bilastine (facing generic competition) and Mesalazine partially offset by Calcifediol. Sales in Portugal keep gaining traction (+11% ...Faes Farma is engaged in the health care research, manufacture and sale of prescription pharmaceuticals, over-the-counter pharmaceuticals and fine chemicals, URGO bandages and dressings and LAZLO cosmetics.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.